PGT-A and immune work-up often central.
PGT-A and immune work-up often central. For recurrent miscarriage, Recurrent loss often points to PGT-A (chromosome screening of embryos) and an immune/clotting work-up.
The chart below shows live-birth rate per embryo transfer from public registries — the single most important number for recurrent miscarriage, because the cost per baby is the country price multiplied by the cycles you are likely to need.
Chart: live-birth % per transfer — donor-egg success stays ~48% at any age, while own-egg success falls with maternal age (SART/CDC 2019, ESHRE/EIM).
Treatment route and the true cost per baby depend on your age and egg situation — model it in the cost-per-baby calculator. For recurrent miscarriage we most often compare Czechia, Greece, Spain, Turkey, Poland.
Recurrent pregnancy loss often points to chromosomally abnormal embryos, so PGT-A (screening embryos before transfer) is frequently central, alongside an immune and clotting work-up. Transferring only euploid embryos reduces miscarriage and shortens the path to a live birth, though it does not raise the underlying egg quality. Maternal age still governs how many normal embryos are available, which is why the registry age curve and the multi-cycle cost-per-baby view both apply here.
Recurrent pregnancy loss often points to chromosomally abnormal embryos. PGT-A (preimplantation genetic testing for aneuploidy) screens embryos before transfer, selecting only euploid (genetically normal) ones. This reduces miscarriage risk and shortens the path to a live birth. However, PGT-A does not raise underlying egg quality; maternal age still governs how many normal embryos are available, which is why the multi-cycle cost-per-baby view applies here.
IVF success is driven mainly by maternal age and egg type, not by the country you choose. The public registries put own-egg live birth at roughly:
The success figures on this page come from national IVF registries, not clinic marketing. Primary sources:
Compiled and fact-checked by the BabyPath editorial team against the registries above. Per-retrieval (CDC) and per-transfer (HFEA) use different denominators — both are shown so the numbers are not misread. Educational information, not medical advice; outcomes vary by individual and clinic — always consult a licensed fertility specialist.
Recurrent loss often points to PGT-A (chromosome screening of embryos) and an immune/clotting work-up.
Own-egg success tracks maternal age — roughly 48% under 35, ~32% at 38–40 and ~8% by 43 — while donor eggs hold near 48% at any age (SART/CDC and ESHRE registries).
We compare Czechia, Greece, Spain, Turkey, Poland on cost per baby, live-birth success and legal eligibility — see the by-destination links below.
Yes — cost per baby is the country price multiplied by the number of cycles you are likely to need, and your diagnosis shifts expected success, so the cheapest sticker price is rarely the cheapest baby.
Often yes, especially under about 38; where ovarian reserve is low, donor eggs can be the cheaper and faster route to a live birth. Model both in the calculator.
The success rates, cost ranges and legal-eligibility rules on this page are compiled from public clinical registries and national guidelines — not opinion. They are planning estimates and do not replace advice from a licensed fertility specialist.
Reviewed against: HFEA (UK), SART/CDC (US), ESHRE/EIM (EU) and NICE CG156.
Compiled and fact-checked by the BabyPath editorial team against the primary sources above · last reviewed 2026-06-12 · BabyPath is an independent cross-border comparison platform, not a clinic. Always consult a licensed clinician before starting treatment.
We compare IVF success rates, prices and laws across 12 countries — using real CDC, HFEA and ESHRE data — to show your true cost per baby, not per cycle. Donor eggs, age 40+, single or same-sex: we show where it's affordable and legal for you.
Get 3 matched clinic quotes — free